Symbols / BCTX
BCTX Chart
About
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.61M |
| Enterprise Value | -3.89M | Income | -28.71M | Sales | — |
| Book/sh | 5.30 | Cash/sh | 5.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -9.41 | PEG | — |
| P/S | — | P/B | 0.69 | P/C | — |
| EV/EBITDA | 0.13 | EV/Sales | — | Quick Ratio | 3.42 |
| Current Ratio | 3.42 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -33.87 | EPS next Y | -0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-10-15 19:00 | ROA | -161.64% |
| ROE | -4.44% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.25M |
| Shs Float | 1.67M | Short Float | 2.29% | Short Ratio | 0.14 |
| Short Interest | — | 52W High | 98.20 | 52W Low | 3.60 |
| Beta | 2.03 | Avg Volume | 432.90K | Volume | 150.02K |
| Target Price | — | Recom | None | Prev Close | $3.76 |
| Price | $3.67 | Change | -2.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.67
Latest analyst target
3. DCF / Fair value
$-45.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.67
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-27 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-04-22 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-02-03 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-19 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- BriaCell (Nasdaq: BCTX) targets 1H2026 topline data in Phase 3 MBC trial under Fast Track - Stock Titan ue, 09 Dec 2025 08
- Why Did BCTX Stock Surge 50% Today? - Stocktwits ue, 13 Jan 2026 08
- BriaCell Therapeutics stock plummets after $30 million offering - Investing.com Wed, 14 Jan 2026 08
- BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - GlobeNewswire Wed, 18 Feb 2026 22
- All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy - Yahoo Finance Fri, 12 Sep 2025 07
- BriaCell Restructures Soluble CD80 Program via BriaPro Deal - TipRanks Fri, 20 Feb 2026 21
- BriaCell (BCTX) Shares Plummet After Announcing Unit Offering | - GuruFocus ue, 15 Jul 2025 07
- What's Going On With BriaCell Therapeutics Stock Wednesday? - Benzinga Wed, 14 Jan 2026 08
- Price Target Adjustments Send BCTX Stock Tumbling - timothysykes.com ue, 13 Jan 2026 08
- BriaCell (NASDAQ: BCTX) receives 4th DSMB recommendation for Phase 3 breast cancer study - Stock Titan Wed, 22 Oct 2025 07
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering - GlobeNewswire hu, 15 Jan 2026 08
- BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com Wed, 09 Jul 2025 07
- BriaCell Announces Proposed Effective Date of Share Consolidation - Yahoo Finance ue, 05 Aug 2025 07
- Why one metastatic breast cancer trial is a key one to watch in 2026 - Stock Titan hu, 18 Dec 2025 08
- 10:1 Share Consolidation: BriaCell Therapeutics Takes Strategic Step to Maintain Nasdaq Capital Market Status - Stock Titan hu, 21 Aug 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 10192 | — | — | Bondarenko (Jamieson) | Director of Issuer | — | 2025-08-25 00:00:00 | D |
| 1 | 169551 | — | — | Del Priore (Giuseppe) | Senior Officer of Issuer | — | 2025-08-25 00:00:00 | D |
| 2 | 574 | — | — | Embro-Pantalony (Vaughn) | Director of Issuer | — | 2025-08-25 00:00:00 | I |
| 3 | 84943 | — | — | Levin (Gadi) | Senior Officer of Issuer | — | 2025-08-25 00:00:00 | D |
| 4 | 84775 | — | — | Lopez-Lago (Miguel A) | Senior Officer of Issuer | — | 2025-08-25 00:00:00 | D |
| 5 | 34 | — | — | Schmieg (Martin E CPA) | Director of Issuer | — | 2025-08-25 00:00:00 | D |
| 6 | 316957 | — | — | Williams (William V) | Director of Issuer | — | 2025-08-25 00:00:00 | D |
| 7 | 188390 | — | — | Del Priore (Giuseppe) | Senior Officer of Issuer | — | 2025-08-01 00:00:00 | D |
| 8 | 94194 | — | — | Levin (Gadi) | Senior Officer of Issuer | — | 2025-08-01 00:00:00 | D |
| 9 | 94194 | — | — | Lopez-Lago (Miguel A) | Senior Officer of Issuer | — | 2025-08-01 00:00:00 | D |
Financials
| Line Item | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -33.06M | -25.34M | -15.13M | -6.95M |
| TotalUnusualItems | 28.22M | 2.08M | -11.69M | -6.77M |
| TotalUnusualItemsExcludingGoodwill | 28.22M | 2.08M | -11.69M | -6.77M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.79M | -20.30M | -26.84M | -13.82M |
| ReconciledDepreciation | 83.90K | 15.27K | 15.27K | 15.26K |
| EBITDA | -4.85M | -23.26M | -26.82M | -13.72M |
| EBIT | -4.93M | -23.27M | -26.84M | -13.74M |
| NetInterestIncome | 288.02K | 891.21K | 135.75K | -75.41K |
| InterestExpense | 0.00 | 979.00 | 78.55K | |
| InterestIncome | 288.02K | 891.21K | 136.73K | 3.15K |
| NormalizedIncome | -33.01M | -22.38M | -15.15M | -7.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.79M | -20.30M | -26.84M | -13.82M |
| TotalExpenses | 33.33M | 23.27M | 15.29M | 6.97M |
| RentExpenseSupplemental | 11.94K | |||
| TotalOperatingIncomeAsReported | -33.33M | -23.27M | -15.29M | -6.97M |
| DilutedAverageShares | 423.11K | 109.70K | 104.13K | 103.29K |
| BasicAverageShares | 423.11K | 109.70K | 104.13K | 103.29K |
| DilutedEPS | -62.19 | -43.68 | -195.00 | -259.50 |
| BasicEPS | -62.19 | -43.68 | -195.00 | -259.50 |
| DilutedNIAvailtoComStockholders | -4.79M | -20.30M | -26.84M | -13.82M |
| NetIncomeCommonStockholders | -4.79M | -20.30M | -26.84M | -13.82M |
| NetIncome | -4.79M | -20.30M | -26.84M | -13.82M |
| MinorityInterests | 140.08K | 0.00 | ||
| NetIncomeIncludingNoncontrollingInterests | -4.93M | -20.30M | -26.84M | -13.82M |
| NetIncomeContinuousOperations | -4.93M | -20.30M | -26.84M | -13.82M |
| PretaxIncome | -4.93M | -20.30M | -26.84M | -13.82M |
| OtherIncomeExpense | 28.11M | 2.08M | -11.69M | -6.77M |
| SpecialIncomeCharges | 0.00 | -141.70K | ||
| OtherSpecialCharges | 141.70K | |||
| EarningsFromEquityInterest | -106.51K | 0.00 | ||
| GainOnSaleOfSecurity | 28.22M | 2.08M | -11.69M | -6.63M |
| NetNonOperatingInterestIncomeExpense | 288.02K | 891.21K | 135.75K | -75.41K |
| TotalOtherFinanceCost | 11.66M | 4.45M | ||
| InterestExpenseNonOperating | 0.00 | 979.00 | 78.55K | |
| InterestIncomeNonOperating | 288.02K | 891.21K | 136.73K | 3.15K |
| OperatingIncome | -33.33M | -23.27M | -15.29M | -6.97M |
| OperatingExpense | 33.33M | 23.27M | 15.29M | 6.97M |
| OtherOperatingExpenses | -3.39K | -3.69K | ||
| DepreciationAmortizationDepletionIncomeStatement | 15.25K | |||
| DepreciationAndAmortizationInIncomeStatement | 15.25K | |||
| Amortization | 15.25K | |||
| AmortizationOfIntangiblesIncomeStatement | 15.25K | |||
| DepreciationIncomeStatement | 15.25K | |||
| ResearchAndDevelopment | 27.18M | 15.34M | 8.02M | 2.02M |
| SellingGeneralAndAdministration | 6.15M | 7.94M | 7.27M | 4.96M |
| GeneralAndAdministrativeExpense | 6.15M | 7.94M | 7.27M | 4.96M |
| OtherGandA | 6.15M | 7.94M | 7.27M | 4.96M |
| InsuranceAndClaims | 318.03K | |||
| RentAndLandingFees | 11.94K | |||
| SalariesAndWages | 2.15M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 121.90K | 106.54K | 103.45K | 101.80K |
| ShareIssued | 121.90K | 106.54K | 103.45K | 101.80K |
| TotalDebt | 25.99K | |||
| TangibleBookValue | -2.58M | -3.99M | 10.10M | 27.43M |
| InvestedCapital | -2.38M | -3.78M | 10.33M | 27.70M |
| WorkingCapital | -3.81M | 25.15M | 41.41M | 57.24M |
| NetTangibleAssets | -2.58M | -3.99M | 10.10M | 27.43M |
| CommonStockEquity | -2.38M | -3.78M | 10.33M | 27.67M |
| TotalCapitalization | -2.38M | -3.78M | 10.33M | 27.70M |
| TotalEquityGrossMinorityInterest | -2.68M | -3.78M | 10.33M | 27.67M |
| MinorityInterest | -302.52K | 0.00 | ||
| StockholdersEquity | -2.38M | -3.78M | 10.33M | 27.67M |
| OtherEquityInterest | 11.03M | 7.42M | 18.37M | |
| GainsLossesNotAffectingRetainedEarnings | -138.68K | -138.68K | -138.68K | -138.68K |
| OtherEquityAdjustments | -138.68K | -138.68K | -138.68K | -138.68K |
| RetainedEarnings | -85.44M | -80.65M | -60.35M | -29.14M |
| AdditionalPaidInCapital | 7.42M | 5.23M | 2.18M | |
| CapitalStock | 72.17M | 69.59M | 65.59M | 54.77M |
| CommonStock | 72.17M | 69.59M | 65.59M | 54.77M |
| TotalLiabilitiesNetMinorityInterest | 8.56M | 30.94M | 32.25M | 30.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.10M | 29.14M | 31.31M | 29.82M |
| DerivativeProductLiabilities | 1.10M | 29.14M | 31.31M | 29.79M |
| LongTermDebtAndCapitalLeaseObligation | 25.99K | |||
| LongTermDebt | 25.99K | |||
| CurrentLiabilities | 7.46M | 1.80M | 941.09K | 556.79K |
| PayablesAndAccruedExpenses | 7.46M | 1.80M | 941.09K | 556.79K |
| CurrentAccruedExpenses | 290.38K | 677.72K | 477.81K | 261.71K |
| Payables | 7.17M | 1.12M | 463.28K | 295.08K |
| OtherPayable | 80.97K | |||
| AccountsPayable | 7.17M | 1.12M | 463.28K | 214.12K |
| TotalAssets | 5.87M | 27.16M | 42.58M | 58.04M |
| TotalNonCurrentAssets | 2.22M | 215.07K | 230.34K | 245.61K |
| NonCurrentPrepaidAssets | 1.21M | 0.00 | ||
| InvestmentsAndAdvances | 418.49K | 2.00 | 2.00 | 2.00 |
| LongTermEquityInvestment | 418.49K | 0.00 | ||
| InvestmentsinSubsidiariesatCost | 418.49K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 199.80K | 215.07K | 230.34K | 245.61K |
| OtherIntangibleAssets | 199.80K | 215.07K | 230.34K | 245.61K |
| NetPPE | 388.18K | 0.00 | ||
| AccumulatedDepreciation | -68.63K | 0.00 | ||
| GrossPPE | 456.80K | 0.00 | ||
| OtherProperties | 456.80K | |||
| CurrentAssets | 3.65M | 26.95M | 42.35M | 57.80M |
| PrepaidAssets | 1.42M | 4.98M | 1.28M | 516.89K |
| Receivables | 1.37M | 717.74K | 24.10K | 12.57K |
| OtherReceivables | 1.37M | 717.74K | ||
| AccountsReceivable | 18.87K | 24.10K | 12.57K | |
| CashCashEquivalentsAndShortTermInvestments | 862.09K | 21.25M | 41.04M | 57.27M |
| CashAndCashEquivalents | 862.09K | 21.25M | 41.04M | 57.27M |
| CashFinancial | 57.27M |
| Line Item | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.58M | -23.74M | -12.48M | -7.75M |
| RepurchaseOfCapitalStock | 0.00 | -47.29K | -10.17M | 0.00 |
| RepaymentOfDebt | 0.00 | -546.11K | ||
| IssuanceOfDebt | 0.00 | 215.71K | ||
| IssuanceOfCapitalStock | 4.42M | 4.00M | 0.00 | 51.62M |
| CapitalExpenditure | -456.80K | |||
| EndCashPosition | 862.09K | 21.25M | 41.04M | 57.27M |
| BeginningCashPosition | 21.25M | 41.04M | 57.27M | 21.25K |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | -20.39M | -19.79M | -16.23M | 57.25M |
| FinancingCashFlow | 4.42M | 3.95M | -3.74M | 65.00M |
| CashFlowFromContinuingFinancingActivities | 4.42M | 3.95M | -3.74M | 65.00M |
| NetOtherFinancingCharges | -80.69K | |||
| ProceedsFromStockOptionExercised | 0.00 | 1.59K | 6.51M | 13.71M |
| NetCommonStockIssuance | 4.42M | 3.95M | -10.17M | 51.62M |
| CommonStockPayments | 0.00 | -47.29K | -10.17M | 0.00 |
| CommonStockIssuance | 4.42M | 4.00M | 0.00 | 51.62M |
| NetIssuancePaymentsOfDebt | 0.00 | -330.40K | ||
| NetShortTermDebtIssuance | 0.00 | -330.40K | ||
| ShortTermDebtPayments | 0.00 | -546.11K | ||
| ShortTermDebtIssuance | 0.00 | 215.71K | ||
| NetLongTermDebtIssuance | -93.94K | |||
| LongTermDebtPayments | -309.64K | |||
| LongTermDebtIssuance | 215.71K | |||
| InvestingCashFlow | -681.80K | 0.00 | 0.00 | |
| CashFlowFromContinuingInvestingActivities | -681.80K | 0.00 | 0.00 | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| NetBusinessPurchaseAndSale | -225.00K | 0.00 | ||
| PurchaseOfBusiness | -225.00K | 0.00 | ||
| NetPPEPurchaseAndSale | -456.80K | 0.00 | ||
| PurchaseOfPPE | -456.80K | 0.00 | ||
| OperatingCashFlow | -24.13M | -23.74M | -12.48M | -7.75M |
| CashFlowFromContinuingOperatingActivities | -24.13M | -23.74M | -12.48M | -7.75M |
| ChangeInWorkingCapital | 7.05M | -3.53M | -391.29K | -2.28M |
| ChangeInPayablesAndAccruedExpense | 5.66M | 860.37K | 384.29K | -2.19M |
| ChangeInAccruedExpense | -387.34K | 199.91K | 135.13K | -785.40K |
| ChangeInPayable | 6.05M | 660.46K | 249.16K | -1.41M |
| ChangeInAccountPayable | 6.05M | 660.46K | 249.16K | -1.41M |
| ChangeInPrepaidAssets | 2.13M | -4.40M | -764.05K | -100.98K |
| ChangeInReceivables | -732.58K | 5.23K | -11.53K | 9.94K |
| OtherNonCashItems | -2.41K | 1.88M | ||
| StockBasedCompensation | 1.80M | 2.19M | 3.07M | 1.97M |
| DepreciationAmortizationDepletion | 83.90K | 15.27K | 15.27K | 15.26K |
| DepreciationAndAmortization | 83.90K | 15.27K | 15.27K | 15.26K |
| AmortizationCashFlow | 15.27K | 15.27K | 15.27K | |
| AmortizationOfIntangibles | 15.27K | 15.27K | 15.27K | |
| Depreciation | 68.63K | 0.00 | ||
| OperatingGainsLosses | -28.14M | -2.12M | 11.66M | 4.49M |
| EarningsLossesFromEquityInvestments | 106.51K | 0.00 | ||
| GainLossOnInvestmentSecurities | -28.24M | -2.12M | 11.66M | 4.45M |
| NetForeignCurrencyExchangeGainLoss | 0.00 | |||
| NetIncomeFromContinuingOperations | -4.93M | -20.30M | -26.84M | -13.82M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|